Investigation announced for Long-Term Investors in shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) over potential Wrongdoing

An investigation was announced for long-term investors in shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) concerning potential breaches of fiduciary duties by certain directors of Capricor Therapeutics, Inc.

Investors who are current long term investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: CAPR stocks follows a lawsuit filed against Capricor Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CAPR stocks, concerns whether certain Capricor Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges that, the defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration, and that the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel, causing Plaintiff and other shareholders to purchase Capricor's securities at artificially inflated prices.

Those who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.